TABLE 2.
Virulence, phenotype, and end point dilution survival assay
| Parental strain | Lueiferase-expressing strain | Virulencea | Phenotypeb | End point survival (%)c of:
|
|
|---|---|---|---|---|---|
| Parental strain | Luciferase-expressing strain | ||||
| SC5314 | CAM 1.1 | Virulent | Hyphal | 32.2 ± 2.5 (5) | 27.6 ± 5.0 (5) |
| ras1/ras1 | CAM 3.1 | Reduced | Pseudohyphal | 9.9 ± 4.9 (3)∗ | 11.2 ± 1.6 (3)∗ |
| cla4/cla4 | CAM 5.2 | Avirulent | Pseudohyphal, aberrant | 48.5 ± 9.9 (5)∗ | 56.8 ± 11.3 (3)∗ |
| cst20/cst20 | CAM 23.3 | Reduced | Hyphal | 22.0 ± 3.5 (4) | 25.2 ± 4.1 (6) |
| cdc35/cdc35 | CAM 26.8 | Avirulent | Yeast | 7.0 ± 2.1 (4)∗ | 7.0 ± 4.4 (4)∗ |
a
Hematogenously disseminated murine model for parental strains.
b
At 37°C, in D-10 medium.
c
Data represent percentages of survival ± standard deviations of the means and are expressed as the numbers of colonies in the presence of RAW264.7 macrophages divided by the number of colonies in the absence of macrophages. Numbers in parentheses indicate numbers of experiments. ∗, significantly different from the wild-type strain of each group (P < 0.01).